Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.48 |
| ▸ | CA2 | P00918 | 3/20 | 0.48 |
| ▸ | CA4 | P22748 | 3/20 | 0.48 |
| ▸ | CA9 | Q16790 | 3/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA3 | P07451 | 1/20 | 0.48 |
| ▸ | CA6 | P23280 | 1/20 | 0.48 |
| ▸ | CA5A | P35218 | 1/20 | 0.48 |
| ▸ | CA7 | P43166 | 1/20 | 0.48 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.48 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.48 |
| ▸ | PTGS2 | P35354 | 9/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.47 |
| ▸ | PDPK1 | O15530 | 3/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 7/20 | 0.46 |
| ▸ | IDO1 | P14902 | 1/20 | 0.45 |
| ▸ | TDO2 | P48775 | 1/20 | 0.45 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL549146 | 0.84 | MPL (0.40) | PTGS2KEAP1IDO1TDO2 | |
| SCHEMBL27813958 | 0.83 | GABRA2 (0.48) | — | |
| SCHEMBL6516304 | 0.82 | GRM2 (0.48) | CA1CA2CA4CA9CA12 | |
| SCHEMBL548171 | 0.81 | POLB (0.47) | PTGS2CYP2C9PTGS1IDO1TDO2 | |
| SCHEMBL5205268 | 0.76 | KEAP1 (0.60) | CA1CA2CA4CA9CA12 | |
| SCHEMBL13743069 | 0.74 | KIF11 (0.65) | CA1CA2CA9CA12PTGS2 | |
| SCHEMBL1656041 | 0.73 | ALOX5AP (0.49) | CA1CA2CA9CA12PTGS2 | |
| SCHEMBL1292999 | 0.72 | PTGS2 (0.42) | CA1CA2CA4CA9CA12 | |
| SCHEMBL3433444 | 0.69 | ALOX5AP (0.39) | CA1CA2CA4CA9CA12 | |
| SCHEMBL1292961 | 0.69 | CA2 (0.45) | CA1CA2CA9CA12CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8110588-B2 | 1,2,3-triazole derivatives useful as modulators of nicotinic acetylcholine receptors | NEUROSEARCH A/S (DK) | 2012-02-07 | — | — | US | claimed |
| US-20100222398-A1 | NOVEL 1,2,3-TRIAZOLE DERIVATIVES USEFUL AS MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | NEUROSEARCH A/S (DK) | 2010-09-02 | — | — | US | claimed |
| CN-101796034-A | Novel 1,2,3-triazole derivatives useful as modulators of nicotinic acetylcholine receptors | NEUROSEARCH AS | 2010-08-04 | — | — | CN | claimed |
| US-8110588-B2 | 1,2,3-triazole derivatives useful as modulators of nicotinic acetylcholine receptors | NEUROSEARCH A/S (DK) | 2012-02-07 | — | — | US | disclosed |
| US-20100222398-A1 | NOVEL 1,2,3-TRIAZOLE DERIVATIVES USEFUL AS MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | NEUROSEARCH A/S (DK) | 2010-09-02 | — | — | US | disclosed |
| CN-101796034-A | Novel 1,2,3-triazole derivatives useful as modulators of nicotinic acetylcholine receptors | NEUROSEARCH AS | 2010-08-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222398-A1 | NOVEL 1,2,3-TRIAZOLE DERIVATIVES USEFUL AS MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | CHRNA3, CHRNB3, CHRNA5 | CA1 3866/4885CA2 3140/4885CA4 3767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.